Biotime sures up 9MIL to advance Cancer program with Cornell Weill
OncoCyte can now advance their cancer programs with partner Cornell Weill.
Anyone interested in following Biotimes cancer development in more depth; please google these 3 news stories from 2011. Subsidiary OncoCyte's 2013 update will be coming soon!
1-January 28, 2011 - BioTime Acquires Assets of Cell Targeting, Inc.
2-August 24, 2011- BioTime’s Subsidiary OncoCyte Corporation Expands Cancer Programs with $10 Million Equity Financing
The last update od PanC-DX was in Jan 2013, article title:
BioTime’s Subsidiary OncoCyte Corporation Provides an Update on the Development of the Novel Pan-Cancer Diagnostic Product PanC-DxTM
Multi-center clinical study of a blood-based diagnostic test for the early detection of cancer planned for 2013